Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 27

1.

Donepezil Plus Solifenacin (CPC-201) Treatment for Alzheimer's Disease.

Chase TN, Farlow MR, Clarence-Smith K.

Neurotherapeutics. 2017 Apr;14(2):405-416. doi: 10.1007/s13311-016-0511-x.

2.

Clinical Recommendations for the Use of Donepezil 23 mg in Moderate-to-Severe Alzheimer's Disease in the Asia-Pacific Region.

Sabbagh M, Han S, Kim S, Na HR, Lee JH, Kandiah N, Phanthumchinda K, Suthisisang C, Senanarong V, Pai MC, Narilastri D, Sowani AM, Ampil E, Dash A.

Dement Geriatr Cogn Dis Extra. 2016 Sep 9;6(3):382-395. eCollection 2016 Sep-Dec. Review.

3.

Translational utility of rodent hippocampal auditory gating in schizophrenia research: a review and evaluation.

Smucny J, Stevens KE, Olincy A, Tregellas JR.

Transl Psychiatry. 2015 Jun 23;5:e587. doi: 10.1038/tp.2015.77. Review.

4.

Cognitive Improvement during Treatment for Mild Alzheimer's Disease with a Chinese Herbal Formula: A Randomized Controlled Trial.

Zhang Y, Lin C, Zhang L, Cui Y, Gu Y, Guo J, Wu D, Li Q, Song W.

PLoS One. 2015 Jun 15;10(6):e0130353. doi: 10.1371/journal.pone.0130353. eCollection 2015.

5.

Depressive symptoms are associated with analgesic use in people with Alzheimer's disease: Kuopio ALSOVA study.

Gilmartin JF, Väätäinen S, Törmälehto S, Bell JS, Lönnroos E, Salo L, Hallikainen I, Martikainen J, Koivisto AM; ALSOVA Study Group.

PLoS One. 2015 Feb 17;10(2):e0117926. doi: 10.1371/journal.pone.0117926. eCollection 2015.

6.

The effects of galantamine treatment on attention and its relationship with cognition and activities of daily living in patients with mild to moderate Alzheimer's disease.

Lee JH, Hong YJ, Bae HJ, Kim BJ, Na DL, Han SH, Park JM, Jeong JH, Cha KR.

J Clin Neurol. 2015 Jan;11(1):66-72. doi: 10.3988/jcn.2015.11.1.66. Epub 2015 Jan 2.

7.

Potential therapeutic strategies for Alzheimer's disease targeting or beyond β-amyloid: insights from clinical trials.

Jia Q, Deng Y, Qing H.

Biomed Res Int. 2014;2014:837157. doi: 10.1155/2014/837157. Epub 2014 Jul 17. Review.

8.

Population pharmacokinetic approach to evaluate the effect of CYP2D6, CYP3A, ABCB1, POR and NR1I2 genotypes on donepezil clearance.

Noetzli M, Guidi M, Ebbing K, Eyer S, Wilhelm L, Michon A, Thomazic V, Stancu I, Alnawaqil AM, Bula C, Zumbach S, Gaillard M, Giannakopoulos P, von Gunten A, Csajka C, Eap CB.

Br J Clin Pharmacol. 2014 Jul;78(1):135-44. doi: 10.1111/bcp.12325.

9.

Evaluating the cognitive effects of donepezil 23 mg/d in moderate and severe Alzheimer's disease: analysis of effects of baseline features on treatment response.

Sabbagh M, Cummings J, Christensen D, Doody R, Farlow M, Liu L, Mackell J, Fain R.

BMC Geriatr. 2013 Jun 6;13:56. doi: 10.1186/1471-2318-13-56.

10.

Long-term safety and tolerability of donepezil 23 mg in patients with moderate to severe Alzheimer's disease.

Tariot P, Salloway S, Yardley J, Mackell J, Moline M.

BMC Res Notes. 2012 Jun 8;5:283. doi: 10.1186/1756-0500-5-283.

11.
12.

Symptomatic and nonamyloid/tau based pharmacologic treatment for Alzheimer disease.

Aisen PS, Cummings J, Schneider LS.

Cold Spring Harb Perspect Med. 2012 Mar;2(3):a006395. doi: 10.1101/cshperspect.a006395. Review.

13.

Collaborative research between academia and industry using a large clinical trial database: a case study in Alzheimer's disease.

Jones R, Wilkinson D, Lopez OL, Cummings J, Waldemar G, Zhang R, Mackell J, Gauthier S.

Trials. 2011 Oct 26;12:233. doi: 10.1186/1745-6215-12-233.

14.

Safety and tolerability of donepezil 23 mg in moderate to severe Alzheimer's disease.

Farlow M, Veloso F, Moline M, Yardley J, Brand-Schieber E, Bibbiani F, Zou H, Hsu T, Satlin A.

BMC Neurol. 2011 May 25;11:57. doi: 10.1186/1471-2377-11-57.

15.
16.

Effectiveness and tolerability of high-dose (23 mg/d) versus standard-dose (10 mg/d) donepezil in moderate to severe Alzheimer's disease: A 24-week, randomized, double-blind study.

Farlow MR, Salloway S, Tariot PN, Yardley J, Moline ML, Wang Q, Brand-Schieber E, Zou H, Hsu T, Satlin A.

Clin Ther. 2010 Jul;32(7):1234-51. doi: 10.1016/j.clinthera.2010.06.019.

17.

Multidimensional classification of hippocampal shape features discriminates Alzheimer's disease and mild cognitive impairment from normal aging.

Gerardin E, Chételat G, Chupin M, Cuingnet R, Desgranges B, Kim HS, Niethammer M, Dubois B, Lehéricy S, Garnero L, Eustache F, Colliot O; Alzheimer's Disease Neuroimaging Initiative.

Neuroimage. 2009 Oct 1;47(4):1476-86. doi: 10.1016/j.neuroimage.2009.05.036. Epub 2009 May 20.

18.

Progress update: Pharmacological treatment of Alzheimer's disease.

Hogan DB.

Neuropsychiatr Dis Treat. 2007;3(5):569-78.

19.

Donepezil in Alzheimer's disease: From conventional trials to pharmacogenetics.

Cacabelos R.

Neuropsychiatr Dis Treat. 2007 Jun;3(3):303-33.

20.

The Item-Specific Deficit Approach to evaluating verbal memory dysfunction: rationale, psychometrics, and application.

Wright MJ, Woo E, Schmitter-Edgecombe M, Hinkin CH, Miller EN, Gooding AL.

J Clin Exp Neuropsychol. 2009 Oct;31(7):790-802. doi: 10.1080/13803390802508918. Epub 2009 Jan 14.

Supplemental Content

Support Center